Today, Charles River Laboratories International Inc. (CRL) Director Sold $326,490.27 in Stock

Today, Charles River Laboratories International Inc. (CRL) Director Sold $326,490.27 in Stock

Charles River Laboratories International Inc. (NYSE:CRL) Director C Richard Reese sold 4,539 shares of the stock in a transaction dated Monday, November 28th. The stock was sold at an average price of $71.93, for a total transaction of $326,490.27. Following the transaction, the director now directly owns 44,943 shares of the company’s stock, valued at $3,232,749.99. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Charles River Laboratories International Inc. (NYSE:CRL) traded up 0.29% during mid-day trading on Tuesday, hitting $71.77. 17,359 shares of the stock traded hands. The stock has a 50 day moving average price of $76.01 and a 200 day moving average price of $81.84. The firm has a market cap of $3.40 billion, a PE ratio of 24.25 and a beta of 1.18. Charles River Laboratories International Inc. has a 12-month low of $65.70 and a 12-month high of $89.18.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, November 2nd. The company reported $1.18 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.13 by $0.05. The firm had revenue of $425.70 million for the quarter, compared to the consensus estimate of $291.20 million. Charles River Laboratories International had a net margin of 9.05% and a return on equity of 25.31%. Charles River Laboratories International’s quarterly revenue was up 21.8% compared to the same quarter last year. During the same period last year, the firm posted $1.03 EPS. On average, analysts expect that Charles River Laboratories International Inc. will post $4.47 earnings per share for the current fiscal year.

Several research firms recently issued reports on CRL. Evercore ISI reissued a “hold” rating and set a $91.50 price target (up from $83.50) on shares of Charles River Laboratories International in a report on Thursday, August 4th. Jefferies Group increased their price target on shares of Charles River Laboratories International from $94.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, August 4th. Citigroup Inc. increased their price target on shares of Charles River Laboratories International from $85.00 to $90.00 and gave the stock a “neutral” rating in a report on Thursday, August 4th. Zacks Investment Research raised shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $96.00 price target for the company in a report on Friday, August 5th. Finally, Credit Suisse Group AG reissued a “neutral” rating on shares of Charles River Laboratories International in a report on Friday, September 30th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and five have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $84.96.

Hedge funds have recently modified their holdings of the stock. First Citizens Bank & Trust Co. increased its stake in shares of Charles River Laboratories International by 0.5% in the third quarter. First Citizens Bank & Trust Co. now owns 6,049 shares of the company’s stock valued at $504,000 after buying an additional 30 shares in the last quarter. Hsbc Holdings PLC increased its stake in shares of Charles River Laboratories International by 1.7% in the second quarter. Hsbc Holdings PLC now owns 3,662 shares of the company’s stock valued at $302,000 after buying an additional 62 shares in the last quarter. Northwestern Mutual Investment Management Company LLC increased its stake in shares of Charles River Laboratories International by 1.0% in the second quarter. Northwestern Mutual Investment Management Company LLC now owns 8,144 shares of the company’s stock valued at $671,000 after buying an additional 84 shares in the last quarter. Alliancebernstein L.P. increased its stake in shares of Charles River Laboratories International by 0.3% in the second quarter. Alliancebernstein L.P. now owns 30,464 shares of the company’s stock valued at $2,511,000 after buying an additional 90 shares in the last quarter. Finally, Eqis Capital Management Inc. increased its stake in shares of Charles River Laboratories International by 2.9% in the third quarter. Eqis Capital Management Inc. now owns 3,485 shares of the company’s stock valued at $290,000 after buying an additional 98 shares in the last quarter. Hedge funds and other institutional investors own 97.17% of the company’s stock.

Charles River Laboratories International Company Profile

Related posts

Leave a Comment